Nexium Control formulation
How Nexium Control works
View the video to learn more about the mode of action of Nexium Control.
The science of Nexium Control
Acid reflux, a cause of heartburn, occurs when the lower oesophageal sphincter relaxes, allowing excess stomach acid (HCl) to enter the oesophagus. Stomach acid is formed by the binding of hydrogen (H+) and chloride (CL-) ions produced by the gastric parietal cells lining the stomach. Nexium Control works by irreversibly binding to the enzyme proton pump that allows the gastric parietal cells to secrete H+ ions, preventing it from working. This reduces the production of stomach acid for up to 24 hours to provide long-lasting heartburn relief.
No other OTC PPI lasts longer1,2
Esomeprazole passes through the liver to the bloodstream more efficiently (with less excretion) compared to omeprazole.2
More than 2 hours longer acid control than omeprazole1,2
- pH>4 for 12.7 hours with esomeprazole vs 10.5 hours with omeprazole
More efficient delivery of acid blockers results in reduced interpatient variability in pharmacodynamic response.4
Antacids and alginates may only provide short acting relief
Antacids react with gastric acid, neutralising it.
Alginates form a temporary physical barrier (or raft) on top of the stomach helping to prevent the contents from escaping through the sphincter. Their effectiveness depends on the stomach contents, with them being less effective if taken during a meal or when lying down.
For both antacids and alginates, once the stomach empties, their effects cease. Repeated dosing is necessary to provide relief from newly secreted acid.
Nexium Control provides long-lasting relief
Nexium Control, with esomeprazole, reduces the production of stomach acid for 24-hour protection, treating the cause and symptoms of heartburn. Allowing time for the oesophagus to recover from the acid irritation.
Protection is achieved with the convenience of once a day dosing*.
*Some people experience relief within a day, though for some, it may take 2 – 3 days for complete relief.
Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.
Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.
*based on volume
Nexium Control 20 mg gastro-resistant tablets and hard capsules (Esomeprazole). Indications: The short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation) in adults.
Dosage: The recommended dose is 20 mg (one tablet or capsule) per day. Tablets or capsules may need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks.
Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir.
Warnings and precautions: Patients should consult a doctor if: They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded to avoid delay in diagnosis. Also, if they have had previous gastric ulcer or gastrointestinal surgery, been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks, have jaundice or severe liver disease, are aged over 55 years with new or recently changed symptoms. Long-term recurrent symptoms of indigestion or heartburn require regular doctor consultation and those over 55 years taking any non-prescription indigestion or heartburn remedy daily should inform their pharmacist or doctor. Nexium Control should not be taken as a long-term preventive product. Treatment with PPIs may lead to a slightly increased risk of GI infections such as Salmonella and Campylobacter and in hospitalised patients, possibly Clostridium difficile. Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test. Co-administration of esomeprazole with atazanavir is not recommended. The potential for interactions with medicinal products metabolised through CYP2C19 should be considered. Concomitant use with clopidogrel is discouraged. Not to be taken with another PPI or H2 antagonist. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. PPIs are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE). If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, medical help should be sought promptly, and discontinuation considered. SCLE after previous treatment with a PPI may increase the risk of SCLE with other PPIs. Contains sugar spheres (sucrose). Not suitable for patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
Side effects: Common: headache and GI disorders, including abdominal pain, constipation, diarrhoea, and nausea/vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash and urticaria. Other side effects are rare, very rare or have an unknown frequency – refer to the SPC for full details.
Legal category: GSL (7s and 14s) and P (28s).
Product licence number: GSL: Capsules PLGB 44673/0221 & Tablets PLGB 44673/0222, P: Tablets PLGB 44673/0225.
MAH: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, Brentford, TW8 9GS
RRP (excl VAT): Tablets: 7s £6.24, 14s £10.83, 28s £18.32. Capsules: 14s £11.66.
Text prepared: Jan 2023